ANOMALI
29.7.2021 17:04:07 CEST | Business Wire | Press release
Anomali , the leader in intelligence-driven cybersecurity solutions, today announced availability of its latest survey conducted by The Harris Poll. The study, which gathered responses from more than 1,000 adults aged 18 and over in the United Kingdom, reveals that more than three-quarters of British adults have cybersecurity fears around the use of COVID-19 digital vaccination cards. Additional findings showed which entities respondents believe are responsible for protecting them against cyberattacks and who they believe the most likely culprits will be.
A majority of respondents predict that a disruptive cyberattack will follow digital vaccine card adoption, findings also reveal confidence levels when it comes to how prepared the nation is to mount a defense. Among key findings:
- 76% have cybersecurity concerns related to COVID-19 digital vaccination cards. Identity theft topped the list at 51%, with fake vaccine cards that could be used to hack smartphones (44%) and data breaches (45%) close behind.
- 89% have smartphones capable of supporting COVID-19 digital vaccination cards. In contrast, a survey conducted a little over a year ago by Anomali and Censuswide showed that half of respondents knew someone that did not possess smartphones necessary to use healthcare technologies such as contract tracing apps.
- 54% say they are “very likely” to use COVID-19 digital vaccination cards if they become a requirement for certain activities, such as traveling, attending sports venues, school attendance, entering a store or government building, etc. However, doubt remains, as 26% said they are “somewhat” likely. A full 21% rejected the idea of using digital vaccine cards, stating they are not likely to use them at all.
- 64% expect that COVID-19 digital vaccination cards will lead to a cyberattack causing “moderate to major” disruption to business, government, and consumers. 27% said that disruption would only be “slight” while 9% do not expect any related disruptions.
- When asked to identify what type of adversary is most likely to carry out a cyberattack related to COVID-19 digital vaccination cards, organized cybercriminal gangs were most frequently cited (42%).
- 64% “somewhat to strongly” agree that government and private business is prepared to defend consumers against a related cyberattack. 74% said the government was most responsible for providing defense.
- Although COVID-19 passport standards haven’t been established, when asked to pick from a list of organizations that will most likely be responsible for creating and managing standards, the government was most frequently cited (55%), the World Health Organization (WHO) came in second (44%).
“Over the course of the pandemic, our intelligence analysts detected thousands of cyberattacks that were taking advantage of people’s desire to consume information online about how COVID-19 was impacting their lives and world. We’ve detected adversaries doing everything from using fake contact tracing apps to hijack smart phones and steal credentials to launching mass phishing campaigns to infect networks with things like ransomware,” said Hugh Njemanze, President, Anomali. “The easing of restrictions, rise in cyberattacks, and consumers’ willingness to use their smartphones to break free from restrictive lockdowns are at a nexus. Organizations responsible for keeping consumers and businesses safe online need to know who the adversaries are, where the attacks are coming from, and how to detect them before they develop into catastrophes.”
- Download the ebook: COVID-19: The Global Health Pandemic and Cybersecurity Challenges
- Read the blog: The COVID-19 Pandemic Changed Everything, Can You Detect the New Normal?
- View the infographic: COVID-19 DIGITAL VACCINE EFFORTS MAY STALL AMID FEARS
Methodology
This survey was conducted online by The Harris Poll on behalf of Anomali from June 30 – July 7, 2021 among 1,007 U.K. adults all ages 18 and older. Raw data were weighted by the following demographic variables where necessary to reflect the general adult population as follows: age, gender, education, region, race, HH size, and marital status. Propensity score weighting was also used to adjust for respondents’ propensity to be online. This online survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated.
Twitter: https://twitter.com/Anomali
LinkedIn: https://www.linkedin.com/company/anomali/
Blog: https://www.anomali.com/blog
About The Harris Poll
The Harris Poll is one of the longest-running surveys in the U.S., tracking public opinion, motivations and social sentiment since 1963. It is now part of Harris Insights & Analytics, a global consulting and market research firm that strives to reveal the authentic values of modern society to inspire leaders to create a better tomorrow. We work with clients in three primary areas; building twenty-first century corporate reputation, crafting brand strategy and performance tracking, and earning organic media through public relations research. Our mission is to provide insights and advisory to help leaders make the best decisions possible.
About Anomali
Anomali is the leader in global intelligence-driven cybersecurity. Our customers rely on us to see and detect threats, stop breaches, stop attackers, elevate resiliency, and improve the productivity of their security operations. Our solutions serve customers around the world in every major industry vertical, including many of the Global 1000. We are a SaaS company that offers native cloud, multi-cloud, on-premises, and hybrid technologies. As an early threat intelligence innovator, Anomali was founded in 2013 and is backed by leading venture firms including Google Ventures, IVP, General Catalyst, and several others. Learn more at www.anomali.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005800/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
